A New Type of Immune Cell Shows Promise in Restoring Tolerance to Type 1 Diabetes

Scientists studying immune tolerance in Type 1 diabetes identified a specific population of regulatory T cells with a distinctive profile: CD8+CD122+ Tregs. These cells appear to play a central role in preventing autoimmune attack on insulin-producing cells. In laboratory models, researchers showed that these donor-derived regulatory T cells could successfully suppress diabetogenic T cells—the very cells that cause Type 1 diabetes.

The study used mixed chimerism, a state where an organism's immune system contains cells from both a donor and recipient. This approach has long been recognized as a way to induce immune tolerance, but the precise mechanisms were not fully understood. This research identified CD8+CD122+ Tregs as key players in that tolerance process.

CD8+CD122+ Tregs display a unique set of characteristics that enable immune suppression. These cells express several markers associated with regulatory function, including Helios, Programmed cell death protein 1, perforin, and granzyme-B. They also show elevated levels of CD39 and Folate receptor 4, while displaying low levels of SCART1, a pro-inflammatory marker.

Remarkably, these regulatory T cells respond specifically to peptide sequences derived from the T cell receptors of islet-attacking autoreactive cells. This means they can recognize and target the very cells causing diabetes, rather than broadly suppressing the immune system. This specificity could be important for developing treatments that control autoimmunity without compromising overall immune function.

When researchers examined blood samples from people with Type 1 diabetes, they found a significant deficiency in CD8+CD122+ Tregs. This suggests that the loss or dysfunction of these protective cells may contribute to the development of Type 1 diabetes. The parallel finding in both mouse models and humans strengthens the case for exploring these cells as a therapeutic target.

The discovery that individuals with Type 1 diabetes lack adequate numbers of these regulatory cells opens a new line of investigation: could restoring or revitalizing CD8+CD122+ Tregs help restore immune tolerance and treat the underlying autoimmunity in Type 1 diabetes?

This research suggests that revitalizing CD8+CD122+ Tregs could represent a new therapeutic strategy for Type 1 diabetes. Rather than simply managing blood sugar, such an approach would target the autoimmune process itself—potentially preventing or slowing the destruction of insulin-producing cells.

The work is still in the research phase, conducted primarily in laboratory models. Much work remains to determine whether similar approaches could be safely and effectively applied in people with Type 1 diabetes. However, the specific and targeted nature of these cells' immune suppression offers a hopeful direction for future investigation.

Source: The Journal of clinical investigation. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.